NVOS Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of -86.61% compared to Novo Integrated Sciences's net margin of 3.36%. Novo Integrated Sciences's return on equity of -49.15% beat Astrana Health's return on equity of 12.67%.

Novo Integrated Sciences has a consensus price target of --, signalling downside risk potential of --. On the other hand Astrana Health has an analysts' consensus of $63.6000 which suggests that it could grow by 103.91%. Given that Astrana Health has higher upside potential than Novo Integrated Sciences, analysts believe Astrana Health is more attractive than Novo Integrated Sciences.

Novo Integrated Sciences has a beta of -0.941, which suggesting that the stock is 194.092% less volatile than S&P 500. In comparison Astrana Health has a beta of 1.196, suggesting its more volatile than the S&P 500 by 19.63%.

Novo Integrated Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Integrated Sciences pays -- of its earnings as a dividend. Astrana Health pays out 102.24% of its earnings as a dividend.

Novo Integrated Sciences quarterly revenues are $3.2M, which are smaller than Astrana Health quarterly revenues of $478.7M. Novo Integrated Sciences's net income of -$2.7M is lower than Astrana Health's net income of $16.1M. Notably, Novo Integrated Sciences's price-to-earnings ratio is -- while Astrana Health's PE ratio is 23.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Integrated Sciences is 0.12x versus 0.86x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Biote has a net margin of -86.61% compared to Novo Integrated Sciences's net margin of 20.83%. Novo Integrated Sciences's return on equity of -49.15% beat Biote's return on equity of --.

Novo Integrated Sciences has a consensus price target of --, signalling downside risk potential of --. On the other hand Biote has an analysts' consensus of $9.87 which suggests that it could grow by 74.13%. Given that Biote has higher upside potential than Novo Integrated Sciences, analysts believe Biote is more attractive than Novo Integrated Sciences.

Novo Integrated Sciences has a beta of -0.941, which suggesting that the stock is 194.092% less volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novo Integrated Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Integrated Sciences pays -- of its earnings as a dividend. Biote pays out 262.18% of its earnings as a dividend.

Novo Integrated Sciences quarterly revenues are $3.2M, which are smaller than Biote quarterly revenues of $51.4M. Novo Integrated Sciences's net income of -$2.7M is lower than Biote's net income of $10.7M. Notably, Novo Integrated Sciences's price-to-earnings ratio is -- while Biote's PE ratio is 21.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Integrated Sciences is 0.12x versus 0.98x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of -86.61% compared to Novo Integrated Sciences's net margin of 13.04%. Novo Integrated Sciences's return on equity of -49.15% beat Cryo-Cell International's return on equity of --.

Novo Integrated Sciences has a consensus price target of --, signalling downside risk potential of --. On the other hand Cryo-Cell International has an analysts' consensus of -- which suggests that it could grow by 21.62%. Given that Cryo-Cell International has higher upside potential than Novo Integrated Sciences, analysts believe Cryo-Cell International is more attractive than Novo Integrated Sciences.

Novo Integrated Sciences has a beta of -0.941, which suggesting that the stock is 194.092% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.542, suggesting its less volatile than the S&P 500 by 45.756%.

Novo Integrated Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 3.38% to investors and pays a quarterly dividend of $0.25 per share. Novo Integrated Sciences pays -- of its earnings as a dividend. Cryo-Cell International pays out -- of its earnings as a dividend.

Novo Integrated Sciences quarterly revenues are $3.2M, which are smaller than Cryo-Cell International quarterly revenues of $8.1M. Novo Integrated Sciences's net income of -$2.7M is lower than Cryo-Cell International's net income of $1.1M. Notably, Novo Integrated Sciences's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Integrated Sciences is 0.12x versus 1.91x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of -86.61% compared to Novo Integrated Sciences's net margin of -12.84%. Novo Integrated Sciences's return on equity of -49.15% beat P3 Health Partners's return on equity of -26.35%.

Novo Integrated Sciences has a consensus price target of --, signalling downside risk potential of --. On the other hand P3 Health Partners has an analysts' consensus of $0.63 which suggests that it could grow by 175.33%. Given that P3 Health Partners has higher upside potential than Novo Integrated Sciences, analysts believe P3 Health Partners is more attractive than Novo Integrated Sciences.

Novo Integrated Sciences has a beta of -0.941, which suggesting that the stock is 194.092% less volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novo Integrated Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Integrated Sciences pays -- of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

Novo Integrated Sciences quarterly revenues are $3.2M, which are smaller than P3 Health Partners quarterly revenues of $362.1M. Novo Integrated Sciences's net income of -$2.7M is higher than P3 Health Partners's net income of -$46.5M. Notably, Novo Integrated Sciences's price-to-earnings ratio is -- while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Integrated Sciences is 0.12x versus 0.03x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.